BioStem Technologies, Inc. (BSEM) Fair Value 2026

BSEM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-27, BioStem Technologies, Inc. (BSEM) trades at $3.85. QOC: 3.8/10. Value Trap Risk: 0/100 (SAFE). 1/13 models active.

Key Facts

Ticker
BSEM
Price
$3.85
Quality Score
3.8/10
Value Trap Risk
0/100
Models Active
1/13
Last Updated
Strength: Regime Cross-Sectional suggests +3.5% upside with 12% confidence
Risk: Below-average Quality Score of 3.8/10 signals weak fundamentals

What Fair Value Does Each Model Give BSEM?

1 Intrinsic Value Models vs. Current Price ($3.85)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $3.98 +3.5%

All Models Active

All 1 models are displayed above.

What Is BioStem Technologies, Inc. (BSEM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BioStem Technologies, Inc.'s intrinsic value is estimated at $3.98, presenting a divided outlook at the current price of $3.85. With a median implied return of +3.5% across a split 0–0 (bull–bear) consensus, the model spread of +0.0% underscores analytical uncertainty.

What Do the Models Say About BSEM?

1 of 13 models are currently active for BSEM. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does BSEM Rank in Biotechnology?

Among 620 Biotechnology stocks, BSEM ranks #544 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, BioStem Technologies, Inc. competes in an environment where cash runway (months) often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is BSEM a Value Trap?

CirclFi's Value Trap algorithm assigns BSEM a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for BioStem Technologies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BioStem Technologies, Inc. is rated at 3.8/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BSEM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BSEM's 1 active models, average confidence is 12%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BioStem Technologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

RNAZTransCode Therapeutics, Inc.QOC 3.9BCLIBrainstorm Cell Therapeutics Inc.QOC 3.8NCNANuCana plcQOC 3.9ACUTAccuStem Sciences, Inc.QOC 3.8TPSTTempest Therapeutics, Inc.QOC 3.9ESLAEstrella Immunopharma, Inc.QOC 3.8ACRSAclaris Therapeutics, Inc.QOC 6.6IMMPImmutep LimitedQOC 5.4NXTCNextCure, Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: RNAZ · BCLI · NCNA · ACUT · TPST · ESLA · ACRS · IMMP · NXTC · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BSEM?

7 companies across all industries closest to BSEM’s Quality of Company score of 3.8/10.

AVEXAEVEX Corp.QOC 3.8GMRSGMR Solutions Inc.QOC 3.8GTICGTICQOC 3.8EICEagle Point Income CompanyQOC 3.8CYCUCycurion, Inc.QOC 3.8OCCIOFS Credit Company, Inc.QOC 3.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AVEX · GMRS · GTIC · EIC · CYCU · OCCI · NVDA

Where Does BSEM Sit in CirclFi's Biotechnology Rankings?

BSEM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About BioStem Technologies, Inc.’s Valuation?

What is BioStem Technologies, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for BioStem Technologies, Inc. (BSEM). The Quality of Company score is 3.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BSEM overvalued or undervalued right now?

At $3.85, 1 of 1 active models suggest BSEM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits BioStem Technologies, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 3.8 mean for BSEM?

BioStem Technologies, Inc.'s QOC of 3.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BSEM?

CirclFi analyzes BSEM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is BSEM a value trap in 2026?

BioStem Technologies, Inc.'s Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns BioStem Technologies, Inc. (BSEM) a Quality of Company score of 3.8/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BSEM/ · Methodology
Primary sources for this BSEM valuation
  • Financial statements: BioStem Technologies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001658678) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BSEM as of ; valuations recomputed .